The most straightforward explanation for this observation is that for patients with more PD-L1-expressing T cells, the PD-1 pathway may be a mechanism of immune escape by these tumours, and therefore these patients would benefit from blocking the PD-1/PD-L1 receptor/ligand interaction. Here, CD274 is linked to neoplasm.